

Review Article

The Role of Posttranslational Protein Modifications in Rheumatological Diseases: Focus on Rheumatoid Arthritis

Andrea Mastrangelo, Tania Colasanti, Cristiana Barbati, Arbi Pecani, Danilo Sabatinelli, Monica Pendolino, Simona Truglia, Laura Massaro, Riccardo Mancini, Francesca Miranda, Francesca Romana Spinelli, Fabrizio Conti, and Cristiano Alessandri

Reumatologia, Dipartimento di Medicina Interna e Specialità Mediche, Sapienza Università di Roma, Italy

Correspondence should be addressed to Cristiano Alessandri; cristiano.alessandri@uniroma1.it

Received 22 September 2014; Revised 16 January 2015; Accepted 5 February 2015

Academic Editor: David Kaplan

Copyright © 2015 Andrea Mastrangelo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The definition of posttranslational modification (PTM) encompasses a wide group of chemical reactions that allow modification and modulation of protein functions. The regulation of PTMs is crucial for the activity and survival of the cells. Dysregulation of PTMs has been observed in several pathological conditions, including rheumatoid arthritis (RA). RA is a systemic autoimmune disease primarily targeting the joints. The three PTMs mainly involved in this disease are glycosylation, citrullination, and carbamylation. Glycosylation is essential for antigen processing and presentation and can modulate immunoglobulin activity. Citrullination of self-antigens is strongly associated with RA, as demonstrated by the presence of antibodies directed to anti-citrullinated proteins in patients' sera. Carbamylation and its dysregulation have been recently associated with RA. Aim of this review is to illustrate the most significant alterations of these PTMs in RA and to evaluate their possible involvement in the pathogenesis of the disease.

1. Introduction

Human cells are able to maintain high levels of efficiency and organization thanks to a complex and finely regulated network of numerous processes (e.g., DNA transcription, protein synthesis). The proper managing of these processes strictly depends on a large group of chemical reactions named posttranslational modifications (PTMs). A PTM consists in every change of chemical structure or property of a protein that occurs after or at the same time of its translation. Nowadays, over 300 PTMs are known [1] and over 200 of them are enzyme-mediated [2], highlighting the attempt of the cell to exploit these modifications for surviving. PTMs are crucial for the development and evolution of every living organism, and it is universally accepted that the more the species are advanced, the better they use and organize PTMs [3]. PTMs and their dysregulations in pathological conditions gained great interest, due to the continuous improvement in biotechnologies that allow better investigation of and definition of these processes.

Rheumatoid arthritis (RA) is an autoimmune disease affecting about 1% of the general population and it is characterized by polyarticular, symmetric involvement of synovial joints, as well as several extra-articular manifestations, such as rheumatoid nodes, pulmonary fibrosis, and accelerated atherosclerosis [4]. The pathogenesis of RA has not been completely elucidated yet and although in these last decades the use of new therapeutic agents has improved the prognosis of the disease, RA is still an important cause of morbidity and disability.

The aim of this review is to give an overview on the role of PTMs in the pathogenesis of RA, focusing on the modifications that have been strongly associated with the disease: glycosylation, citrullination, and carbamylation (Table 1).

2. Glycosylation in Rheumatoid Arthritis

Glycosylation consists in the addition of sugars on nitrogen (N-glycosylation) or oxygen (O-glycosylation) atoms of the side chain of the protein amino acids. This reaction is

TABLE 1: Summary of some posttranslational modifications in rheumatoid arthritis.

PTM	Effect(s)	Reference
Glycosylation: PTM that consists in the addition of glucides on an atom of nitrogen (N-glycosylation) or oxygen (O-glycosylation) of the lateral chain of the amino acids that forms a protein.	Epitopes presentation: -Protein glycosylation interacts with the processes of antigen presentation. -These interactions regard both antigen processing pathways in APCs and TCR-MHC II complex formation.	Haurum et al., 1999 [6] Jefferis et al., 1995 [22]
	Igs properties: -Fc fragment of immunoglobulins has an important site of N-glycosylation, the asparagine 297 (Asn297). -It has been shown that IgG can have both proinflammatory and anti-inflammatory activity, depending on which Fcγ receptor they preferentially bind to: those different affinities for receptors are strictly dependent on the composition of the saccharine lateral chain linked to Asn297.	Goulabchand et al., 2014 [23]
Citrullination: PTM consisting in the switch of the imine nitrogen of an arginine to an atom of oxygen, linked to the backbone structure as a ketone. It is mediated by a family of enzymes called PAD (or PADI).	-It is associated with histone modification, genomic regulation and NET formation. -PAD activation can be an intracellular or extracellular event, due to various conditions. -This activation can lead to the creation of altered self-epitopes and ACPA formation.	Yamada et al., 2005 [49] Khandpur et al., 2013 [60]
Carbamylation: Nonenzymatic PTM that consists in the addition of a cyanate group on proteins.	-Loss of the native proteic structure. This event can lead to a break of tolerance and finally results in the formation of anti-CarP autoantibodies.	Shi et al., 2011 [90]

ACPA: anti-citrullinated protein antibodies; anti-CarP: anti-carbamylated protein; APC: antigen presenting cell; NET: neutrophil extracellular trap; PAD: peptidylarginine deiminase; PTM: posttranslational modification.

mediated by hundreds of glycosyl-transferases (GTs), regulated basically at transcriptional level. Human cells modify simple sugars, such as glucose or galactose, in more complex ones, in order to create a larger number of precursors for glycosylation; subsequently, the linking of uridine diphosphate or, rarely, cytosine monophosphate activates the sugars. Glycosylation occurs on both extracellular and intracellular proteins and it is crucial for several vital processes such as proteins folding or cell-to-cell interactions [5]. Glycosylation is involved in two physiopathological processes—epitope presentation to immune system and immunoglobulins- (Igs-) mediated regulation of immune response—suggesting a possible association of aberrant glycosylation with RA (Figure 1). Furthermore, aberrant glycosylation of different plasma proteins was demonstrated in RA patients.

2.1. Glycosylation and Epitope Presentation. Glycosylation affects the antigen presentation acting both on antigen processing pathways in antigen presenting cells (APCs) and on T cell receptor- (TCR-) MHC II complex formation.

Glycosylation plays an important role in antigen presentation by modifying the cleavage of proteins in both proteasome (MHC I-associated pathway) and endosome (MHC II-associated pathway). A considerable number of cytosolic peptides presented on MHC I molecules carry an O-glycosylation with a molecule of N-acetyl-glucosamine (GlcNAc) [6]. The O-GlcNAcylation is a PTM that interacts with phosphorylation [7] to regulate several intracellular processes, such as the activation of nuclear transcription factors and the responses to nutrient deprivation. Abolishing

or modifying the physiological O-GlcNAcylation processes, as observed during inflammation or other responses to stressful stimuli [8], could determine the presentation of new antigenic glycopeptides on MHC I molecules that can bind to autoreactive T cells.

Regarding MHC II-associated pathway, it was demonstrated that different glycoforms of the same protein are processed in different ways, generating different peptides linked on MHC II molecules; this process can lead to the presentation of cryptic self-antigens or to an enhanced presentation of normally nonimmunodominant self-antigens [9].

During the antigen presentation, APCs are not capable of cleaving the side sugar chains; so, if a certain peptide carries a glycan side chain, the whole glycan-peptide complex will be presented on MHC II molecule. This process may improve or diminish TCR affinity for the MHC-peptide complex by steric interference [10].

Glycosylation influences T lymphocyte activation. Many studies investigated T cell responses to subtypes of collagen II-derived peptides in mice with collagen induced arthritis (CIA) [11, 12]. Corthay and coworkers pointed out that the response to these peptides is strictly dependent on the PTM carried on lysine 264 (K264). B10.Q mice showed a strong response to galactosylated K264 and a very weak response to unmodified or hydroxylated K264 collagen derived peptides [13]. As expected, mice immunization with galactosylated K264/MHC II complex reduced the severity of arthritis and the extent of the humoral [anti-type II collagen (anti-CII) antibodies] immune response [14]. Recently, Batsalova et al.




FIGURE 1: Aberrant glycosylation affects antigen presentation and can induce breaking of tolerance. (Of note, due to the cross-presentation pathway, intracellular proteins with altered glycosylation could be presented on MHC II molecules to T CD4⁺).

demonstrated that DR4 transgenic mice (expressing human HLA-DR4 allele) are more responsive to the unmodified or hydroxylated K264 compared to the galactosylated one [15]. These results are in accordance with the previous observation that collagen from human and rats with active arthritis contains glycosylated and unglycosylated zones; on the contrary, in healthy subjects collagen is uniformly glycosylated [16]. Besides collagen, other proteins—for example, p68—show a glycosylation-dependent T cell recognition [17]; hence, an aberrant glycosylation might be one of the triggers for the onset and progression of RA.

Infections as well lead to an alteration of self-protein glycosylation. *E. coli* is able to modify glycosylation of self-proteins, due to its own GTs expression [18]. *H. pylori* CagA toxin could also alter the glycosylation processes in B lymphocytes [19]. Moreover, the cytokine secretion induced by these (and other) pathogens is able to modify the cellular pattern of GTs [20, 21]. All together, these events could be a rational explanation for the theory of “infection-triggered autoimmunity.”

2.2. Glycosylation and Immunoglobulin Properties. As previously mentioned, glycosylation may affect the immune system also by modifying IgG properties. Fc fragment of IgGs has an important site of N-glycosylation, the 297 asparagine (N297). IgGs can exert both proinflammatory and anti-inflammatory activities depending on which Fc γ receptor they preferentially bind: the different receptor affinity strictly depends on the composition of the sugar side chain linked to N297 [22, 23]. The phenotype associated with a higher

proinflammatory activity displays low levels of galactose and sialic acid [24]; differently, the anti-inflammatory phenotype is characterized by normal galactose and sialic acid and reduced GlcNAc levels [25, 26]. IgGs can exert their anti-inflammatory effects also by binding to other receptors: whether this interaction is dependent or not on Fc fragment glycosylation is still unclear [27–29]. Different factors, such as interleukins or lipopolysaccharide, can induce a proinflammatory pattern of the sugars linked to IgGs [30, 31]. This whole process finally leads to a vicious circle of self-sustaining immune activation.

In active RA, anti-citrullinated peptide antibodies (ACPA) and rheumatoid factor (RF) display the proinflammatory N297 glycosylation pattern, with low levels of galactose and sialic acid [32–34]. These autoantibodies acquire this glycosylation pattern before the clinical onset of the disease [35]; interestingly, changes in IgGs glycosylation were associated with RA remission observed during pregnancy [36, 37]. Taken together, these observations remark the crucial role of IgG glycosylation in the pathogenesis of the disease.

Many circulating proteins can also display an altered glycosylation in RA [38–40]. For example, lubricin isolated by synovial fluid of RA patients expresses an aberrant glycan determinant and shows an L-selectin ligand activity that may induce the activation of neutrophils and polymorphonuclear cells [40].

A good response to therapy turns the IgGs glycosylation back to a noninflammatory phenotype [41]. In order to stop the vicious circle triggered by the altered IgGs glycosylation,

Nandakumar et al. proposed a treatment with endostreptosin (EndoS)—a bacteric glycosidase able to trim the whole N297 side chain. *In vitro* incubation of anti-CII monoclonal antibodies with EndoS prevents the onset of arthritis in mice; this effect persists even if antibodies-EndoS are injected together with anti-CII antibodies [42].

Some authors hypothesized a possible treatment of severe RA and, in general, of autoimmune diseases with sialic acid enriched-intravenous Igs; however, the preliminary results are not conclusive and call for further researches [43, 44].

3. Citrullination and Rheumatoid Arthritis

Citrullination is a protein modification consisting in the switch of the iminic nitrogen of arginine to oxygen, linked to the backbone structure as a ketone; this process results in the production of an amino acid called citrulline. The reaction is mediated by a family of enzymes called peptidylarginine deiminase (PAD or PADI) [45] (Figure 2). Nowadays, 5 subtypes of PAD (PADI-6), variously distributed in human cells, are known [46, 47]. The activity of these enzymes is regulated by intracellular Ca^{2+} concentration. The subtypes of PAD expressed by the immune cells are PAD4 and PAD2, markedly present in neutrophils and mast cells [48]. The switch from arginine to citrulline has several different consequences on protein structure: the oxygen of citrulline is a noncharged atom, differently from the positive-charged nitrogen of arginine; since side chain charge of the amino acid sequence is crucial for the protein folding, an alteration in the electronic milieu modifies the tertiary structure of the peptide [49]. So far, citrullination is associated with histone modifications, neutrophils extracellular trap (NET) formation, and epidermal, central nervous system and skeletal muscle tropism regulation [47].

Immunogenicity of citrullinated proteins has been studied, especially in autoimmune diseases such as RA, leading to the identification of ACPA. Nowadays, ACPA are essential in RA diagnosis: the presence of these autoantibodies, revealed with the ACPA assays, has a specificity of 85–95% and a sensitivity of about 80% [50].

ACPA can be identified in about 50% of RA patients approximately 1 year before the onset of arthritis [51]. Higher titre of ACPA at diagnosis is considered a negative prognostic factor and ACPA titre seems to be reduced after treatment [52, 53]. Furthermore, citrullinated antigens recognized by ACPA are abundant in inflamed synovia; among the others, alpha-1 antitrypsin, fibrinogen, apolipoproteins, histones, immunoglobulins, and vimentin had been characterized [54].

All these findings depose even for a pathological role of these autoantibodies in the development of RA.

Two questions arising from these data still remain partially unsolved: why do RA patient antibodies recognize as “non-self” the citrullinated proteins? And how citrullinated antigens are produced?

The first question found a partial answer in the strong association between ACPA-positive RA and specific HLA polymorphisms, especially the conserved region of HLA-DRB1*0104 allele: subjects who carry this allele have an higher risk of developing an erosive ACPA-positive RA,

due to the ability of the HLA molecule coded by this specific haplotype to bind and present citrullinated antigens [55]. Nevertheless, this haplotype is also diffused in healthy population. Other susceptibility genes have been identified, but altogether they represent only 50% of genetic variance associated with ACPA-positive arthritis [56]. Clearly, more studies are needed to elucidate the physiopathological pathway leading to ACPA formation.

The latter question is much more complex. In fact, even if the final step of citrullination always consists in the activation of the PAD-family enzymes, the modulation of this pathway is variable and still not completely understood.

Summarizing, the processes leading to the formation of citrullinated epitopes can result in an accumulation of citrullinated proteins at extracellular and/or intracellular levels, which will be subsequently described.

3.1. Extracellular Accumulation. Extracellular accumulation of citrullinated proteins is related to two main factors: NET formation and *P. gingivalis* infection. NETosis is a powerful defensive mechanism developed by immune system in order to trap and destroy extracellular bacteria. NETs are constituted by loose chromatin complexed with many antimicrobial enzymes stored in neutrophils granules; this whole complex is expelled by the cell in the extracellular space. The negative charge of chromatin traps the bacteria, allowing the enzymes to kill the microorganisms [57]. To undergo NETosis, neutrophils need PAD4 activation: the histone citrullination mediated by this enzyme causes chromatin relaxation that is crucial for the subsequent processes [58]. NETosis has been associated with several pathological conditions, like thrombosis, multiple sclerosis, and RA [59]. In RA, several alterations in NET formation have been noticed. When compared to healthy subjects, neutrophils isolated by the peripheral blood of RA patients undergo NETosis more easily; NETosis can be induced by RF or ACPA and, finally, the enzyme load of the chromatin shows differences between NETs of RA patients and healthy subjects [60].

In an inflammatory contest, such as the rheumatoid synovia, NETs release citrullinated antigens [61]: in RA predisposed individuals, synovial citrullinated antigens may be caught and presented to T lymphocytes, promoting a local immune response.

P. gingivalis, a Gram negative, nonmotile, anaerobic bacterium, is considered the major causative agent of periodontitis in humans [62]. Periodontitis is an inflammation of the structures surrounding the teeth, affecting about 50% of the adult population [63]. It is also a well-studied risk factor for the development of RA [64], since *P. gingivalis* is the only bacterium able to synthesize its own PAD [65]. This bacterium can lead to an increase in citrullination of host periodontium proteins, creating new citrullinated epitopes [66].

Arandjelovic et al. hypothesized a new pathway for extracellular citrullination: *in vitro*, ATP from dying cells can bind an ATP-receptor on mast cells and promote the activation and the release in the extracellular space of PAD2 [67].




FIGURE 2: Biochemical process that occurs in protein citrullination event.

3.2. Intracellular Accumulation. Several mechanisms of intracellular accumulation of citrullinated proteins have been demonstrated *in vitro* and they represent an interesting field of research.

Autophagy is a cellular process consisting in the fusion of lysosomal vacuoles with vacuoles coming from intracellular elements, in order to digest them and restore energetic and nutrient reserve. Autophagy plays an important role in the regulation of intracellular organelle turnover [68]. Physiologically, this process occurs in starvation or under other stressful conditions for the cell and it has been also associated with several pathological conditions [69], including RA. During amino acid deprivation in B lymphocyte cell cultures, the induction of autophagy pathways leads to the intracellular activation of PAD and to the citrullination of self-peptides occurring during the MHC-peptide complex formation; moreover, treatment of B lymphocytes with both anti-IgG and anti-IgM results in an enhanced presentation of citrullinated antigens, abrogated by the addition of autophagy inhibitors; *in vivo*, the same mechanism may be mediated by RF [70].

Romero et al. demonstrated that membrane disruption can cause intracellular citrullination. This group showed that neutrophils treated with granzyme/perforin B or complement membrane attack complex undergo necrosis; the loss of membrane integrity led to a massive influx of Ca²⁺ and to an uncontrolled activation of PAD enzymes. The so-called hypercitrullination deriving from these events produces an elevated number of citrullinated proteins. Therefore, it can be hypothesized that *in vivo* an immune response directed to neutrophils could result in the formation of self-citrullinated antigens with a subsequent breaking of tolerance [71].

3.3. Smoking and Citrullination. Smoking is a risk factor for the development of ACPA-positive RA, especially in people who present HLA-DRB*0104 allele [72]. This habit

can increase the formation of citrullinated proteins and promote an activation of the immune system. Nanoparticles inhaled with tobacco smoke can lead to the activation of PAD2 and PAD4 inside the cells [73]. Smoke effects on the cells include upregulation of PAD2 expression and subsequent citrullination [74].

To point out the crucial role of other predisposing factors in the onset of RA, Bongartz et al. revealed that lung biopsies of smokers that have developed lung cancer did not show any intracellular protein citrullination, in contrast with the strong intracellular protein citrullination detected in RA affected smokers [75].

3.4. PAD Inhibitors. Recently, several authors studied inhibitors of PAD for the treatment of RA. Cl-amidine, a pan-PAD inhibitor, showed an efficacy in mice with CIA in reducing severity of disease, synovial citrullination, and histological joint damage [76]. Another PAD inhibitor, the compound named YW3-56, showed a 5-fold increase in PAD4 activity inhibition, if compared with Cl-amidine. YW3-56 has been tested as anticancer drug, but its ability in blocking PAD4 could make it a good candidate also for the treatment of RA [77].

4. Carbamylation and Rheumatoid Arthritis

Carbamylation is a nonenzymatic PTM that consists in the addition of a cyanate group (O=C=N⁻) on self-proteins [78]. This reaction usually affects the atoms of nitrogen, although a certain degree of carbamylation has also been demonstrated on sulphur atoms [79]. Free nitrogen atoms in proteins can be found at the N-terminus or in the side chain of lysine and arginine. The most important carbamylation detected in patient with RA is the lysine carbamylation: this chemical process leads to the formation of homocitrulline, a noncanonical amino acid, through the link of the carbon atom of cyanate with the nitrogen atom of the lysine [80].




FIGURE 3: Protein carbamylation: causes and consequences. Several conditions can shift the balance between urea and cyanate towards cyanate production, enhancing in this way the process of protein carbamylation. This event results in systemic effects and production of anti-CarP autoantibodies.

Cyanate required for carbamylation can be produced in two different ways.

The first way is the spontaneous degradation of blood urea. In fact, urea is in equilibrium with cyanate [81], and the equilibrium in cyanate-urea ratio *in vivo* seems to oscillates around 1 : 200 [82].

The second way consists in cyanate intake from the external environment. Cyanate is found at a concentration of about 200 parts-per-trillion by volume in urban air and can be detected in both tobacco and biomass smoke [83]; potassium and sodium cyanate are used in several herbicides [84]; finally, many foods (e.g., broccoli) possess a moderate quantity of thiocyanate that, reacting with reactive oxygen species, can be converted in cyanate [85, 86].

In healthy individuals, the concentration of blood cyanate is about 50 nmol/L, an amount that is 1000 times lower than the expected one, according to urea kinetic equilibrium [87]. For some authors, this alteration can be explained with a sort of “physiological carbamylation” of N-terminus of blood proteins [88].

Carbamylation is time dependent: structural proteins, due to their slow turnover, are indeed much more likely to be carbamylated, if compared to proteins with shorter half-life [89].

Carbamylation of self-proteins causes a loss of the native proteic structure and can lead to a break of tolerance, finally resulting in the formation of anti-carbamylated proteins (anti-CarP) autoantibodies (Figure 3). These autoantibodies

can be detected in RA patients. Inhibition assays demonstrated that ACPA and anti-CarP are 2 different families of autoantibodies [90].

Immunization with homocitrullinated peptides can cause T and B cell mediated immune response against the synovial membrane, and the intrarticular injection of homocitrulline-containing peptides can result in the development of a mild arthritis even in nonimmunized mice. Interestingly, in the study of Mydel and coworkers it was demonstrated that mice immunization with homocitrulline followed by the intrarticular injection of citrullinated or homocitrullinated peptides determined a severe arthritis in a higher percentage of the first group (more than 90%), suggesting this an unexpected response as a final linkage between alteration in citrullination and severe arthritis development [91].

Anti-CarP autoantibodies can be detected in about 16% of seronegative RA patients; their presence is correlated to a more severe and erosive disease [90] and represents a risk factor for developing RA in patients with inflammatory arthralgia [92]. Anti-CarP autoantibodies have been detected in RA patients’ sera before the clinical manifestation of disease [93]. So, they appear to be a new useful tool in the diagnosis and follow-up of RA.

5. Conclusion

PTMs are certainly implicated in the development of RA and in several other autoimmune and nonautoimmune diseases.

Nowadays, many aspects of RA pathogenesis have been understood, thanks to the large number of studies focusing on the role of PTMs in the induction of this disease. However, none of the theories proposed to explain the exact aetiology of RA is completely exhaustive. Every single PTM alteration alone is not sufficient to ignite the disease, so overlap of multiple alterations seems to be needed for the onset of RA in predisposed patients.

The challenge for the future studies is to find a linkage between the various PTM alterations that occur during the development of RA, in order to identify possible steps leading to the breaking of self-tolerance and to the clinical onset of the disease. Improving knowledge in the pathogenesis of RA could offer new suggestions for the development of more effective drugs.

Conflict of Interests

The authors have no conflict of interests to declare. The authors alone are responsible for the content and writing of the paper.

References

- [1] Y. Zhao and O. N. Jensen, "Modification-specific proteomics: strategies for characterization of post-translational modifications using enrichment techniques," *Proteomics*, vol. 9, no. 20, pp. 4632–4641, 2009.
- [2] C. Walsh, *Posttranslational Modification of Proteins: Expanding Nature's Inventory*, Roberts and Co., 2006.
- [3] R. D. Emes, A. J. Pocklington, C. N. G. Anderson et al., "Evolutionary expansion and anatomical specialization of synapse proteome complexity," *Nature Neuroscience*, vol. 11, no. 7, pp. 799–806, 2008.
- [4] D. L. Scott, F. Wolfe, and T. W. J. Huizinga, "Rheumatoid arthritis," *The Lancet*, vol. 376, no. 9746, pp. 1094–1108, 2010.
- [5] A. Varki, H. Freeze, and P. Gagneux, *Essentials of Glycobiology*, Cold Spring Harbor Laboratory Press, 2nd edition, 2008.
- [6] J. S. Haurum, I. B. Høier, G. Arsequell et al., "Presentation of cytosolic glycosylated peptides by human class I major histocompatibility complex molecules in vivo," *Journal of Experimental Medicine*, vol. 190, no. 1, pp. 145–150, 1999.
- [7] J. W. Bullen, J. L. Balsbaugh, D. Chanda et al., "Cross-talk between two essential nutrient-sensitive enzymes: O-GlcNAc transferase (OGT) and AMP-activated protein kinase (AMPK)," *Journal of Biological Chemistry*, vol. 289, no. 15, pp. 10592–10606, 2014.
- [8] N. E. Zachara, N. O'Donnell, W. D. Cheung, J. J. Mercer, J. D. Marth, and G. W. Hart, "Dynamic O-GlcNAc modification of nucleocytoplasmic proteins in response to stress: a survival response of mammalian cells," *The Journal of Biological Chemistry*, vol. 279, no. 29, pp. 30133–30142, 2004.
- [9] A. W. Purcell, I. R. van Driel, and P. A. Gleeson, "Impact of glycans on T-cell tolerance to glycosylated self-antigens," *Immunology and Cell Biology*, vol. 86, no. 7, pp. 574–579, 2008.
- [10] B. A. Cobb and D. L. Kasper, "Coming of age: carbohydrates and immunity," *European Journal of Immunology*, vol. 35, no. 2, pp. 352–356, 2005.
- [11] E. Michaëlsson, M. Andersson, Å. Engström, and R. Holmdahl, "Identification of an immunodominant type-II collagen peptide recognized by T cells in H-2q mice: self tolerance at the level of determinant selection," *European Journal of Immunology*, vol. 22, no. 7, pp. 1819–1825, 1992.
- [12] B.-Y. Diab, N. C. Lambert, F.-E. L'Faqihi, P. Loubet-Lescoulié, C. De Préval, and H. Coppin, "Human collagen II peptide 256–271 preferentially binds to HLA-DR molecules associated with susceptibility to rheumatoid arthritis," *Immunogenetics*, vol. 49, no. 1, pp. 36–44, 1999.
- [13] A. Corthay, J. Bäcklund, J. Broddefalk et al., "Epitope glycosylation plays a critical role for T cell recognition of type II collagen in collagen-induced arthritis," *European Journal of Immunology*, vol. 28, no. 8, pp. 2580–2590, 1998.
- [14] B. Dzhambazov, K. S. Nandakumar, J. Kihlberg, L. Fugger, R. Holmdahl, and M. Vestberg, "Therapeutic vaccination of active arthritis with a glycosylated collagen type II peptide in complex with MHC class II molecules," *The Journal of Immunology*, vol. 176, no. 3, pp. 1525–1533, 2006.
- [15] T. Batsalova, I. Lindh, J. Bäcklund, B. Dzhambazov, and R. Holmdahl, "Comparative analysis of collagen type II-specific immune responses during development of collagen-induced arthritis in two B10 mouse strains," *Arthritis Research & Therapy*, vol. 14, no. 6, article R237, 2012.
- [16] B. Dzhambazov, M. Holmdahl, H. Yamada et al., "The major T cell epitope on type II collagen is glycosylated in normal cartilage but modified by arthritis in both rats and humans," *European Journal of Immunology*, vol. 35, no. 2, pp. 357–366, 2005.
- [17] S. Bläss, C. Meier, H. W. Vohr, M. Schwochau, C. Specker, and G. R. Burmester, "The p68 autoantigen characteristic of rheumatoid arthritis is reactive with carbohydrate epitope specific autoantibodies," *Annals of the Rheumatic Diseases*, vol. 57, no. 4, pp. 220–225, 1998.
- [18] O. Y. Goodwin, M. S. Thomasson, A. J. Lin, M. M. Sweeney, and M. A. Macnaughtan, "E. coli sabotages the in vivo production of O-linked β -N-acetylglucosamine-modified proteins," *Journal of Biotechnology*, vol. 168, no. 4, pp. 315–323, 2013.
- [19] M. Yang, F.-G. Li, X.-S. Xie, S.-Q. Wang, and J.-M. Fan, "CagA, a major virulence factor of *Helicobacter pylori*, promotes the production and underglycosylation of IgA1 in DAKIKI cells," *Biochemical and Biophysical Research Communications*, vol. 444, no. 2, pp. 276–281, 2014.
- [20] J. C. Nolz and J. T. Harty, "IL-15 regulates memory CD⁸⁺ T cell O-glycan synthesis and affects trafficking," *The Journal of Clinical Investigation*, vol. 124, no. 3, pp. 1013–1026, 2014.
- [21] P. Delmotte, S. Degroote, J.-J. Lafitte, G. Lamblin, J.-M. Perini, and P. Roussel, "Tumor necrosis factor α increases the expression of glycosyltransferases and sulfotransferases responsible for the biosynthesis of sialylated and/or sulfated Lewis x epitopes in the human bronchial mucosa," *Journal of Biological Chemistry*, vol. 277, no. 1, pp. 424–431, 2002.
- [22] R. Jefferis, J. Lund, and M. Goodall, "Recognition sites on human IgG for Fc γ receptors: the role of glycosylation," *Immunology Letters*, vol. 44, no. 2-3, pp. 111–117, 1995.
- [23] R. Goulabchand, T. Vincent, F. Batteux, J. F. Eliaou, and P. Guilpain, "Impact of autoantibody glycosylation in autoimmune diseases," *Autoimmunity Reviews*, vol. 13, no. 7, pp. 742–750, 2014.
- [24] W. Louthrenoo, N. Kasitanon, R. Wichainun et al., "Anti-agalactosyl IgG antibodies in Thai patients with rheumatoid arthritis, systemic lupus erythematosus, and systemic sclerosis," *Clinical Rheumatology*, vol. 29, no. 3, pp. 241–246, 2010.

- [25] S. Böhm, I. Schwab, A. Lux, and F. Nimmerjahn, "The role of sialic acid as a modulator of the anti-inflammatory activity of IgG," *Seminars in Immunopathology*, vol. 34, no. 3, pp. 443–453, 2012.
- [26] Y. Kaneko, F. Nimmerjahn, and J. V. Ravetch, "Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation," *Science*, vol. 313, no. 5787, pp. 670–673, 2006.
- [27] X. Yu, S. Vasiljevic, D. A. Mitchell, M. Crispin, and C. N. Scanlan, "Dissecting the molecular mechanism of IVIg therapy: the interaction between serum IgG and DC-SIGN is independent of antibody glycoform or Fc domain," *Journal of Molecular Biology*, vol. 425, no. 8, pp. 1253–1258, 2013.
- [28] I. K. Campbell, S. Miescher, D. R. Branch et al., "Therapeutic effect of IVIG on inflammatory arthritis in mice is dependent on the Fc portion and independent of sialylation or basophils," *The Journal of Immunology*, vol. 192, no. 11, pp. 5031–5038, 2014.
- [29] R. M. Anthony and J. V. Ravetch, "A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs," *Journal of Clinical Immunology*, vol. 30, supplement 1, pp. S9–S14, 2010.
- [30] J. Wang, C. I. A. Balog, K. Stavenhagen et al., "Fc-glycosylation of IgG1 is modulated by B-cell stimuli," *Molecular & Cellular Proteomics*, vol. 10, no. 5, 2011.
- [31] C. Hess, A. Winkler, A. K. Lorenz et al., "T cell-independent B cell activation induces immunosuppressive sialylated IgG antibodies," *The Journal of Clinical Investigation*, vol. 123, no. 9, pp. 3788–3796, 2013.
- [32] S. Albrecht, L. Unwin, M. Muniyappa, and P. M. Rudd, "Glycosylation as a marker for inflammatory arthritis," *Cancer Biomarkers*, vol. 14, no. 1, pp. 17–28, 2014.
- [33] H. U. Scherer, J. Wang, R. E. M. Toes et al., "Immunoglobulin 1 (IgG1) Fc-glycosylation profiling of anti-citrullinated peptide antibodies from human serum," *PROTEOMICS—Clinical Applications*, vol. 3, no. 1, pp. 106–115, 2009.
- [34] A. Matsumoto, K. Shikata, F. Takeuchi, N. Kojima, and T. Mizuochi, "Autoantibody activity of IgG rheumatoid factor increases with decreasing levels of galactosylation and sialylation," *Journal of Biochemistry*, vol. 128, no. 4, pp. 621–628, 2000.
- [35] Y. Rombouts, E. Ewing, L. A. van de Stadt et al., "Anti-citrullinated protein antibodies acquire a pro-inflammatory Fc glycosylation phenotype prior to the onset of rheumatoid arthritis," *Annals of the Rheumatic Diseases*, vol. 74, no. 1, pp. 234–241, 2015.
- [36] F. E. van de Geijn, M. Wuhler, M. H. J. Selman et al., "Immunoglobulin G galactosylation and sialylation are associated with pregnancy-induced improvement of rheumatoid arthritis and the postpartum flare: results from a large prospective cohort study," *Arthritis Research and Therapy*, vol. 11, no. 6, article R193, 2009.
- [37] A. Bondt, M. H. J. Selman, A. M. Deelder et al., "Association between galactosylation of immunoglobulin G and improvement of rheumatoid arthritis during pregnancy is independent of sialylation," *Journal of Proteome Research*, vol. 12, no. 10, pp. 4522–4531, 2013.
- [38] A. Saroha, S. Kumar, B. P. Chatterjee, and H. R. Das, "Jaccalin bound plasma O-glycoproteome and reduced sialylation of alpha 2-HS glycoprotein (A2HSG) in rheumatoid arthritis patients," *PLoS ONE*, vol. 7, no. 10, Article ID e46374, 2012.
- [39] S. A. Flowers, L. Ali, C. S. Lane, M. Olin, and N. G. Karlsson, "Selected reaction monitoring to differentiate and relatively quantitate isomers of sulfated and unsulfated core 1 O-glycans from salivary MUC7 protein in rheumatoid arthritis," *Molecular and Cellular Proteomics*, vol. 12, no. 4, pp. 921–931, 2013.
- [40] C. Jin, A.-K. H. Ekwall, J. Bylund et al., "Human synovial lubricin expresses sialyl Lewis x determinant and has L-selectin ligand activity," *The Journal of Biological Chemistry*, vol. 287, no. 43, pp. 35922–35933, 2012.
- [41] A. Croce, O. Firuzi, F. Altieri et al., "Effect of infliximab on the glycosylation of IgG of patients with rheumatoid arthritis," *Journal of Clinical Laboratory Analysis*, vol. 21, no. 5, pp. 303–314, 2007.
- [42] K. S. Nandakumar, M. Collin, K. E. Happonen et al., "Dominant suppression of inflammation by glycan-hydrolyzed IgG," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 110, no. 25, pp. 10252–10257, 2013.
- [43] I. Schwab, S. Mihai, M. Seeling, M. Kasperkiewicz, R. J. Ludwig, and F. Nimmerjahn, "Broad requirement for terminal sialic acid residues and FcγRIIB for the preventive and therapeutic activity of intravenous immunoglobulins in vivo," *European Journal of Immunology*, vol. 44, no. 5, pp. 1444–1453, 2014.
- [44] T. Guhr, J. Bloem, N. I. L. Derksen et al., "Enrichment of sialylated IgG by lectin fractionation does not enhance the efficacy of immunoglobulin G in a murine model of immune thrombocytopenia," *PLoS ONE*, vol. 6, no. 6, Article ID e21246, 2011.
- [45] W. J. van Venrooij and G. J. M. Pruijn, "Citrullination: a small change for a protein with great consequences for rheumatoid arthritis," *Arthritis Research*, vol. 2, no. 4, pp. 249–251, 2000.
- [46] E. R. Vossenaar, A. J. W. Zendman, W. J. van Venrooij, and G. J. M. Pruijn, "PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease," *BioEssays*, vol. 25, no. 11, pp. 1106–1118, 2003.
- [47] Z. Baka, B. György, P. Géher, E. I. Buzás, A. Falus, and G. Nagy, "Citrullination under physiological and pathological conditions," *Joint Bone Spine*, vol. 79, no. 5, pp. 431–436, 2012.
- [48] E. R. Vossenaar, T. R. D. Radstake, A. van Der Heijden et al., "Expression and activity of citrullinating peptidylarginine deiminase enzymes in monocytes and macrophages," *Annals of the Rheumatic Diseases*, vol. 63, no. 4, pp. 373–381, 2004.
- [49] R. Yamada, A. Suzuki, X. Chang, and K. Yamamoto, "Citrullinated proteins in rheumatoid arthritis," *Frontiers in Bioscience*, vol. 10, no. 1, pp. 54–64, 2005.
- [50] R. Aggarwal, K. Liao, R. Nair, S. Ringold, and K. H. Costenbader, "Anti-citrullinated peptide antibody assays and their role in the diagnosis of rheumatoid arthritis," *Arthritis Care & Research*, vol. 61, no. 11, pp. 1472–1483, 2009.
- [51] L. A. van de Stadt, M. H. M. T. de Koning, R. J. van De Stadt et al., "Development of the anti-citrullinated protein antibody repertoire prior to the onset of rheumatoid arthritis," *Arthritis & Rheumatism*, vol. 63, no. 11, pp. 3226–3233, 2011.
- [52] K. Forslind, M. Ahlmén, K. Eberhardt, I. Hafström, and B. Svensson, "Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP)," *Annals of the Rheumatic Diseases*, vol. 63, no. 9, pp. 1090–1095, 2004.
- [53] C. Alessandri, M. Bombardieri, N. Papa et al., "Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFα therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement," *Annals of the Rheumatic Diseases*, vol. 63, no. 10, pp. 1218–1221, 2004.
- [54] J. J. B. C. van Beers, C. M. Schwarte, J. Stammen-Vogelzangs, E. Oosterink, B. Božič, and G. J. M. Pruijn, "The rheumatoid

- arthritis synovial fluid citrullinome reveals novel citrullinated epitopes in apolipoprotein E, myeloid nuclear differentiation antigen, and β -actin," *Arthritis & Rheumatism*, vol. 65, no. 1, pp. 69–80, 2013.
- [55] S. W. Scally, J. Petersen, S. C. Law et al., "A molecular basis for the association of the *HLA-DRB1* locus, citrullination, and rheumatoid arthritis," *The Journal of Experimental Medicine*, vol. 210, no. 12, pp. 2569–2582, 2013.
- [56] R. R. P. de Vries, D. van der Woude, J. J. Houwing, and R. E. M. Toes, "Genetics of ACPA-positive rheumatoid arthritis: the beginning of the end?" *Annals of the Rheumatic Diseases*, vol. 70, no. 1, pp. i51–i54, 2011.
- [57] Q. Remijsen, T. W. Kuijpers, E. Wirawan, S. Lippens, P. Vandenebeele, and T. Vanden Berghe, "Dying for a cause: NETosis, mechanisms behind an antimicrobial cell death modality," *Cell Death and Differentiation*, vol. 18, no. 4, pp. 581–588, 2011.
- [58] M. Leshner, S. Wang, C. Lewis et al., "PAD4 mediated histone hypercitrullination induces heterochromatin decondensation and chromatin unfolding to form neutrophil extracellular trap-like structures," *Frontiers in Immunology*, vol. 3, article 307, 2012.
- [59] N. Branzk and V. Papayannopoulos, "Molecular mechanisms regulating NETosis in infection and disease," *Seminars in Immunopathology*, vol. 35, no. 4, pp. 513–530, 2013.
- [60] R. Khandpur, C. Carmona-Rivera, A. Vivekanandan-Giri et al., "NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis," *Science Translational Medicine*, vol. 5, no. 178, Article ID 178ra40, 2013.
- [61] J. Spengler, B. Lugonja, A. Creese et al., "Synovial fluid neutrophils undergoing NETosis contribute to joint inflammation by producing citrullinated autoantigens," *Annals of the Rheumatic Diseases*, vol. 72, supplement 1, article A10, 2013.
- [62] A. L. Griffen, M. R. Becker, S. R. Lyons, M. L. Moeschberger, and E. J. Leys, "Prevalence of *Porphyromonas gingivalis* and periodontal health status," *Journal of Clinical Microbiology*, vol. 36, no. 11, pp. 3239–3242, 1998.
- [63] P. I. Eke, B. A. Dye, L. Wei, G. O. Thornton-Evans, and R. J. Genco, "Prevalence of periodontitis in adults in the united states: 2009 and 2010," *Journal of Dental Research*, vol. 91, no. 10, pp. 914–920, 2012.
- [64] T. R. Mikuls, J. B. Payne, F. Yu et al., "Periodontitis and porphyromonas gingivalis in patients with rheumatoid arthritis," *Arthritis & Rheumatology*, vol. 66, no. 5, pp. 1090–1100, 2014.
- [65] N. Wegner, R. Wait, A. Sroka et al., "Peptidylarginine deiminase from *Porphyromonas gingivalis* citrullinates human fibrinogen and α -enolase: implications for autoimmunity in rheumatoid Arthritis," *Arthritis & Rheumatism*, vol. 62, no. 9, pp. 2662–2672, 2010.
- [66] W. Nesse, J. Westra, J. E. van der Wal et al., "The periodontium of periodontitis patients contains citrullinated proteins which may play a role in ACPA (anti-citrullinated protein antibody) formation," *Journal of Clinical Periodontology*, vol. 39, no. 7, pp. 599–607, 2012.
- [67] S. Arandjelovic, K. R. McKenney, S. S. Leming, and K. A. Mowen, "ATP induces protein arginine deiminase 2-dependent citrullination in mast cells through the P2X7 purinergic receptor," *The Journal of Immunology*, vol. 189, no. 8, pp. 4112–4122, 2012.
- [68] L. Klareskog, V. Malmström, K. Lundberg, L. Padyukov, and L. Alfredsson, "Smoking, citrullination and genetic variability in the immunopathogenesis of rheumatoid arthritis," *Seminars in Immunology*, vol. 23, no. 2, pp. 92–98, 2011.
- [69] B. M. Mohamed, N. K. Verma, A. M. Davies et al., "Citrullination of proteins: a common post-translational modification pathway induced by different nanoparticles in vitro and in vivo," *Nanomedicine*, vol. 7, no. 8, pp. 1181–1195, 2012.
- [70] D. Makrygiannakis, M. Hermansson, A.-K. Ulfgrén et al., "Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells," *Annals of the Rheumatic Diseases*, vol. 67, no. 10, pp. 1488–1492, 2008.
- [71] V. Romero, J. Fert-Bober, P. A. Nigrovic et al., "Immune-mediated pore-forming pathways induce cellular hypercitrullination and generate citrullinated autoantigens in rheumatoid arthritis," *Science Translational Medicine*, vol. 5, no. 209, Article ID 209ra150, 2013.
- [72] D. Glick, S. Barth, and K. F. Macleod, "Autophagy: cellular and molecular mechanisms," *The Journal of Pathology*, vol. 221, no. 1, pp. 3–12, 2010.
- [73] P. Jiang and N. Mizushima, "Autophagy and human diseases," *Cell Research*, vol. 24, no. 1, pp. 69–79, 2014.
- [74] J. M. Ireland and E. R. Unanue, "Autophagy in antigen-presenting cells results in presentation of citrullinated peptides to CD4 T cells," *The Journal of Experimental Medicine*, vol. 208, no. 13, pp. 2625–2632, 2011.
- [75] T. Bongartz, T. Cantaert, S. R. Atkins et al., "Citrullination in extra-articular manifestations of rheumatoid arthritis," *Rheumatology*, vol. 46, no. 1, pp. 70–75, 2007.
- [76] V. C. Willis, A. M. Gizinski, N. K. Banda et al., "N- α -benzoyl-N5-(2-chloro-1-iminoethyl)-L-ornithine amide, a protein arginine deiminase inhibitor, reduces the severity of murine collagen-induced arthritis," *The Journal of Immunology*, vol. 186, no. 7, pp. 4396–4404, 2011.
- [77] Y. Wang, P. Li, S. Wang et al., "Anticancer peptidylarginine deiminase (PAD) inhibitors regulate the autophagy flux and the mammalian target of rapamycin complex 1 activity," *The Journal of Biological Chemistry*, vol. 287, no. 31, pp. 25941–25953, 2012.
- [78] G. R. Stark, W. H. Stein, and S. Moore, "Reactions of the cyanate present in aqueous urea with amino acids and proteins," *The Journal of Biological Chemistry*, vol. 235, no. 11, pp. 3177–3181, 1960.
- [79] G. R. Stark, "On the reversible reaction of cyanate with sulfhydryl groups and the determination of NH₂-terminal cysteine and cystine in proteins," *The Journal of Biological Chemistry*, vol. 239, no. 5, pp. 1411–1414, 1964.
- [80] A. Willemze, R. E. M. Toes, T. W. J. Huizinga, and L. A. Trouw, "New biomarkers in rheumatoid arthritis," *The Netherlands Journal of Medicine*, vol. 70, no. 9, pp. 392–399, 2012.
- [81] P. Hagel, J. J. T. Gerding, W. Fiegggen, and H. Bloemendal, "Cyanate formation in solutions of urea. I. Calculation of cyanate concentrations at different temperature and pH," *Biochimica et Biophysica Acta*, vol. 243, no. 3, pp. 366–373, 1971.
- [82] J. S. Claxton, P. C. Sandoval, G. Liu, C.-L. Chou, J. D. Hoffert, and M. A. Knepper, "Endogenous carbamylation of renal medullary proteins," *PLoS ONE*, vol. 8, no. 12, Article ID e82655, 2013.
- [83] J. M. Roberts, P. R. Veres, A. K. Cochran et al., "Isocyanic acid in the atmosphere and its possible link to smoke-related health effects," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 108, no. 22, pp. 8966–8971, 2011.
- [84] R. C. Baldwin, A. Pasi, J. T. MacGregor, and C. H. Hine, "The rates of radical formation from the dipyridylum herbicides paraquat, diquat, and morfamquat in homogenates of rat lung,

- kidney, and liver: an inhibitory effect of carbon monoxide," *Toxicology and Applied Pharmacology*, vol. 32, no. 2, pp. 298–304, 1975.
- [85] C. A. Sanchez, B. C. Blount, L. Valentin-Blasini, and R. I. Krieger, "Perchlorate, thiocyanate, and nitrate in edible cole crops (*Brassica* sp.) produced in the lower Colorado River region," *Bulletin of Environmental Contamination and Toxicology*, vol. 79, no. 6, pp. 655–659, 2007.
- [86] J. Chung and J. L. Wood, "Oxidation of thiocyanate to cyanide and sulfate by the lactoperoxidase-hydrogen peroxide system," *Archives of Biochemistry and Biophysics*, vol. 141, no. 1, pp. 73–78, 1970.
- [87] S. Jaisson, C. Pietrement, and P. Gillery, "Carbamylation-derived products: bioactive compounds and potential biomarkers in chronic renal failure and atherosclerosis," *Clinical Chemistry*, vol. 57, no. 11, pp. 1499–1505, 2011.
- [88] I. Koshiishi and T. Imanari, "State analysis of endogenous cyanate ion in human plasma," *Journal of Pharmacobiodynamics*, vol. 13, no. 4, pp. 254–258, 1990.
- [89] C. M. Balion, T. F. Draisey, and R. J. Thibert, "Carbamylated hemoglobin and carbamylated plasma protein in hemodialyzed patients," *Kidney International*, vol. 53, no. 2, pp. 488–495, 1998.
- [90] J. Shi, R. Knevel, P. Suwannalai et al., "Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 108, no. 42, pp. 17372–17377, 2011.
- [91] P. Mydel, Z. Wang, M. Brisslert et al., "Carbamylation-dependent activation of T cells: a novel mechanism in the pathogenesis of autoimmune arthritis," *Journal of Immunology*, vol. 184, no. 12, pp. 6882–6890, 2010.
- [92] J. Shi, L. A. van de Stadt, E. W. N. Levarht et al., "Anti-carbamylated protein antibodies are present in arthralgia patients and predict the development of rheumatoid arthritis," *Arthritis & Rheumatism*, vol. 65, no. 4, pp. 911–915, 2013.
- [93] J. Shi, L. A. van de Stadt, E. W. N. Levarht et al., "Anti-carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis," *Annals of the Rheumatic Diseases*, vol. 73, no. 4, pp. 780–783, 2014.